The Clinical Candidate VT-1161 Is a Highly Potent Inhibitor of Candida albicans CYP51 but Fails To Bind the Human Enzyme

The binding and cytochrome P45051 (CYP51) inhibition properties of a novel antifungal compound, VT-1161, against purified recombinant Candida albicans CYP51 (ERG11) and Homo sapiens CYP51 were compared with those of clotrimazole, fluconazole, itraconazole, and voriconazole. VT-1161 produced a type I...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: Warrilow, A. G. S., Hull, C. M., Parker, J. E., Garvey, E. P., Hoekstra, W. J., Moore, W. R., Schotzinger, R. J., Kelly, D. E., Kelly, S. L.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2014
Sujets:
Experimental Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4249504/
https://ncbi.nlm.nih.gov/pubmed/25224009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.03707-14
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires